Saturday, December 13, 2025 7:17:56 PM
While I rarely post directly back to bashers, I will this time.
I believe on gaining approval we'll have a few billion dollar market cap, equating to a share price of $2 or more. Where we go from there may depend on what LP has to say at the Annual Meeting. I'm not certain approval will precede the meeting, but believe it will. If I'm right, we'll end the year at $2 or more.
As for next year, if we have the cleanroom and EDEN approved by the end of the second quarter, I believe we'll be able to supply at least 1000 patients a month. As I see it, one EDEN will produce 4 batches a month so 1000 a month will require 250 EDEN Units. If we say that NWBO earns $100K from each batch, that would equate to earning $1.2 billion a year. I believe that a company with earnings growth that's substantial each quarter should get a P/E of 30, but we won't have earned all that much in the year, so let's say we're valued at 20 times what we're earning, or 24 billion. If by chance we have 2.4 billion shares outstanding, that's $10 a share.
By that time I think we'll be approved in many countries who choose to piggy-back on the UK decision, and I suspect we'll have a PDUFA date from the FDA.
I also suspect that thousands of additional EDEN's will be coming on line, some in new hubs, many in new spokes supported by those hubs as that model becomes universally accepted.
If we grow faster, we could be worth more, slower, less. I also believe a few new trials will be initiated. If one or more are co-sponsored it's very possible that that too will add to our market cap, even if they're not taking equity, and if they do become equity partners, I believe the company moves close to the market cap price they're paying, and I believe that will be a value equaling at least a $20 billion market cap, and probably significantly more.
Of course I could be wrong on either high, or low side, but as long as we gain approval, I doubt that we'd be under $5 at the end of the year. On the high side, anything is possible, but over $25 would be a surprise on the up side. It's most likely we'll end 2026 between $10 and $20 and yes we'll be on a major exchange, but I'm unsure of which one.
Gary
I believe on gaining approval we'll have a few billion dollar market cap, equating to a share price of $2 or more. Where we go from there may depend on what LP has to say at the Annual Meeting. I'm not certain approval will precede the meeting, but believe it will. If I'm right, we'll end the year at $2 or more.
As for next year, if we have the cleanroom and EDEN approved by the end of the second quarter, I believe we'll be able to supply at least 1000 patients a month. As I see it, one EDEN will produce 4 batches a month so 1000 a month will require 250 EDEN Units. If we say that NWBO earns $100K from each batch, that would equate to earning $1.2 billion a year. I believe that a company with earnings growth that's substantial each quarter should get a P/E of 30, but we won't have earned all that much in the year, so let's say we're valued at 20 times what we're earning, or 24 billion. If by chance we have 2.4 billion shares outstanding, that's $10 a share.
By that time I think we'll be approved in many countries who choose to piggy-back on the UK decision, and I suspect we'll have a PDUFA date from the FDA.
I also suspect that thousands of additional EDEN's will be coming on line, some in new hubs, many in new spokes supported by those hubs as that model becomes universally accepted.
If we grow faster, we could be worth more, slower, less. I also believe a few new trials will be initiated. If one or more are co-sponsored it's very possible that that too will add to our market cap, even if they're not taking equity, and if they do become equity partners, I believe the company moves close to the market cap price they're paying, and I believe that will be a value equaling at least a $20 billion market cap, and probably significantly more.
Of course I could be wrong on either high, or low side, but as long as we gain approval, I doubt that we'd be under $5 at the end of the year. On the high side, anything is possible, but over $25 would be a surprise on the up side. It's most likely we'll end 2026 between $10 and $20 and yes we'll be on a major exchange, but I'm unsure of which one.
Gary
Bullish
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
